MedTrace Logo

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

NCT05200442 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2026-05-08

No results posted yet for this study

Summary

Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatment or individuals who cannot take/tolerate previous treatments. If you choose to participate, your time in this research will last up to 24 months.

Conditions

  • Colorectal Cancer
  • Colorectal Adenocarcinoma
  • Colorectal Cancer Metastatic
  • Advanced Colorectal Carcinoma
  • Advanced Colorectal Adenocarcinoma

Interventions

DRUG

VS-6766/avutometinib

An oral anti-cancer medication.

DRUG

Cetuximab

A chemotherapy drug used to treat head, neck and colorectal cancer.

OTHER

Pill Diary

A diary where participants in phase 2 of study will log their medications and times they are taken on study.

Sponsors & Collaborators

  • Verastem, Inc.

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Ardaman S. Shergill, MD · University of Chicago Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-22
Primary Completion
2027-05-01
Completion
2027-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200442 on ClinicalTrials.gov